Source: International Congress 2015 – New data on established treatments for COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Seil Sagar (Lund, Sweden), Seil Sagar, Mandy Menzel, Leif Bjermer, Lena Uller. Anticholinergic treatment does not affect toll-like receptor 3-induced antiviral immune response in COPD bronchial epithelial cells. Eur Respir J 2015; 46: Suppl. 59, 1497

Member's Comments

No comment yet.

Related content which might interest you: Effects of dexamethasone and anti-inflammatory drugs on inflammatory cytokines from bronchial epithelial cells of COPD patients Source: International Congress 2015 – New insights into lung disease pathogenesis Year: 2015 Platelet activating factor receptor (PAFr) expression is increased in airways of COPD patients but is not attenuated by inhaled corticosteroid (ICS) Source: Annual Congress 2013 –COPD: new markers of diseases Year: 2013 Azithromycin augments rhinovirus-induced expression of IFNbeta and IFNλ1 in asthmatic bronchial epithelial cells by up-regulating RIG-I like receptors Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 TSPO a new anti-inflammatory target in the airway of COPD Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015 Repeated lipopolysaccharide stimulation causes corticosteroid insensitive inflammation in lung via phosphoinositide-3-kinase δ signaling Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 PTX3 a marker of innate immune responses in the airways of asthmatics and COPD patients Source: Annual Congress 2013 –Asthma: new mechanisms and markers Year: 2013 Evidence for cell mediated immune dysfunction in the COPD lung: The role of cytotoxic CD4+ T cells Source: International Congress 2015 – Viral infections: basic research and clinical perspective Year: 2015 Anti-inflammatory effects of roflumilast N-oxide and dexamethasone in human bronchial epithelial cells stimulated with toll-like receptor agonists Source: Annual Congress 2013 –The pulmonary epithelium: recent developments Year: 2013 Additive anti-inflammatory effect of glucocorticoids and PDE4 inhibitors on COPD CD8 cells Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Macrolide effects on the prevention of COPD exacerbations Source: Eur Respir J 2012; 40: 485-494 Year: 2012 Disease specific effects of adrenomedullin in COPD and asthma derived human bronchial epithelial cells Source: International Congress 2015 – Immunomodulation: basic science and clinical aspects Year: 2015 AZD7624, an inhaled p38 inhibitor for COPD, attenuates lung and systemic inflammation after LPS Challenge in humans Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015 Toll-like receptor (TLR)-signaling mediates enhanced inflammatory effects in coinfections of viral and bacterial respiratory pathogens in human lung tissue – A new approach to the pathogenesis of COPD exacerbations? Source: Annual Congress 2011 - Insight into mechanisms of respiratory infections Year: 2011 COPD airway epithelium secretion attracts and activates neutrophils Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 Comprehensive toll-like receptor stimulation and cytokine analysis in precision-cut lung slices Source: International Congress 2016 – Studies in airway cell biology Year: 2016 Differential effect of fluticasone on Poly(I:C) induced TSLP secretion by bronchial epithelial cells from asthmatic children Source: International Congress 2016 – Mechanisms of disease Year: 2016 Cell therapy by adipose stromal cells affect tracheal responsiveness and inflammatory responses in guinea pigs model of COPD Source: International Congress 2015 – New models for treating airway diseases Year: 2015 Activation of the β-catenin pathway by Wnt-1 treatment suppress inflammation in the mouse model of allergic airway disease Source: International Congress 2015 – Advances in asthma and allergy in animal models Year: 2015 Aerobic training reverses the inhibition in the expression of glucocorticoid receptors and decreases the Th2 allergic inflammation in asthma model Source: Annual Congress 2013 –The multiple faces of stress in lung injury Year: 2013 Anti-inflammatory effects of the novel phosphodiesterase type 4 inhibitor CHF6001 on COPD alveolar macrophages and lung tissue Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014